Research article

**Novel IL10 gene family associations with systemic juvenile idiopathic arthritis**

Mark S Fife¹, Ana Gutierrez¹, Emma M Ogilvie¹, Carmel JW Stock¹, Jane M Samuel¹, Wendy Thomson², Lisa F Mack², Cathryn M Lewis³ and Patricia Woo¹

¹Centre of Pediatric and Adolescent Rheumatology, Windeyer Institute for Medical Sciences, University College London, Cleveland Street, London W1T 4JF, UK
²ARC Epidemiology Unit, University of Manchester, Manchester, UK
³Guy’s, Kings and St Thomas’ School of Medicine, London, UK

Corresponding author: Mark S Fife, m.fife@ucl.ac.uk

Received: 10 May 2006 Revisions requested: 21 Jun 2006 Revisions received: 19 Jul 2006 Accepted: 7 Sep 2006 Published: 7 Sep 2006

Arthritis Research & Therapy 2006, 8(R148) (doi:10.1186/ar2041)
This article is online at: http://arthritis-research.com/content/8/5/R148
© 2006 Fife et al.; licensee BioMed Central Ltd.
This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**Abstract**

Juvenile idiopathic arthritis (JIA) is the most common cause of chronic childhood disability and encompasses a number of disease subgroups. In this study we have focused on systemic JIA (sJIA), which accounts for approximately 11% of UK JIA cases. This study reports the investigation of three members of the IL10 gene family as candidate susceptibility loci in children with sJIA. DNA from 473 unaffected controls and 172 patients with sJIA was genotyped for a single nucleotide polymorphism (SNP) in IL19 and IL20 and two SNPs in IL10. We examined evidence for association of the four SNPs by single marker and haplotype analysis. Significant differences in allele frequency were observed between cases and controls, for both IL10-1082 (p = 0.031) and IL20-468 (p = 0.028). Furthermore, examination of the haplotypes of IL10-1082 and IL20-468 revealed greater evidence for association (global p = 0.0006). This study demonstrates a significant increased prevalence of the low expressing IL10-1082 genotype in patients with sJIA. In addition, we show a separate association with an IL20 polymorphism, and the IL10-1082A/IL20-468T haplotype. The two marker ‘A-T’ haplotype confers an odds ratio of 2.24 for sJIA. This positive association suggests an important role for these cytokines in sJIA pathogenesis.

**Introduction**

Juvenile idiopathic arthritis (JIA) is the most common cause of childhood disability, with an incidence of 1 in 10 000 children under the age of 16 [1]. It is a clinically heterogeneous group of complex diseases, with polygenic and environmental factors all playing a role in aetiology. There are seven clinically distinct subtypes of JIA [2]. The most severe and least responsive to current therapies is systemic JIA (sJIA), a disease defined by a quotidian fever and one or more manifestations, including an evanescent rash, lymphadenopathy, hepatomegaly or splenomegaly, or serositis. While HLA associations are a significant genetic factor in other JIA subtypes, there are no associations with Caucasian sJIA [3]. However, a number of non-HLA genes have been reported to be associated with sJIA, including those encoding IL6 and Macrophage inhibitory factor [4,5].

IL10 is a cytokine with potent immunoregulatory and anti-inflammatory properties. It acts to suppress the release and function of a number of pro-inflammatory cytokines, including IL1, tumour necrosis factor (TNF)-α, and IL6 [6]. Low levels of IL10 production associated with autoimmune disease, such as rheumatoid arthritis, psoriasis, and collagen-induced arthritis, suggest defective regulatory roles of IL10 in limiting inflammation and reversing immunopathology. However, IL10 is also a stimulatory factor for mast cells, B cells, and thymocytes [7,8].

In the upstream regulatory region of the gene encoding IL10, the three most characterised single nucleotide polymorphisms (SNPs) are at positions -1,082 (G to A), -819 (C to T) and -592 (C to A) [9,10]. There is absolute linkage disequilibrium (LD) between the IL10-819 and IL10-592 SNPs. In the Caucasian populations only three out of the remaining four possible haplotypes occur: GCC, ACC and ATA. We have...
previously shown that stimulation of human whole blood cultures with bacterial lipopolysaccharide (LPS) results in a large variation between individuals in IL10 secretion. When examined in the context of IL10 genotype, it was revealed that the ATA/ATA genotype is associated with significantly lower IL10 production [11,12]. In addition, we also showed a significantly increased frequency of this low-expressing ATA haplotype in extended juvenile oligoarthritis. There is strong evidence to support genetic control of IL10 levels, with production levels showing concordance in monozygotic twins and a genetic component of over 75% [13]. Turner and colleagues [9] demonstrated that the difference in IL10 secretion is associated with the presence or absence of an 'A' at position -1,082 of the human IL10 promoter.

In the severe forms of JIA, treatment is often limited to high doses of glucocorticoids. It is of interest, therefore, that pre-treatment with IL10 improves the ability of dexamethasone in suppressing IL6 (a cytokine correlated with sJIA disease activity) in whole-blood cultures (p < 0.01) [14]. Furthermore, LPS-stimulated whole blood cultures from sJIA patients showed reduced levels of IL10 compared to healthy, age matched controls [11]. This reduced capacity of sJIA patients to produce sufficient quantities of this anti-inflammatory cytokine may suggest a pathogenic role for IL10 in this disease.

Two recently described members of the IL10 family are IL19 and IL20. The genes encoding these cytokines are located within a highly conserved cytokine gene cluster in 1q32. Like the T-Helper 2 (TH2) IL4 cytokine gene cluster, recent evidence from the mouse IL10 gene family cluster suggests that there is coordinate regulation of these cytokines by distal regulatory elements spanning the locus [15]. Both IL19 and IL20 are produced by a diverse range of cell types, including monocyte/macrophages, T- cells and keratinocytes [16]. Interestingly, long-term exposure of T cells to IL19 and IL20 down-regulated interferon-γ but up-regulated IL4 and IL13 and supported the polarisation of naïve T cells to Th2-like cells [17]. Apart from significant genetic association of Hepatitis C virus clearance with IL10/19 and IL20, and psoriasis with IL19/20 loci. Additional patients were also recruited from the Outpatient Departments at both Great Ormond Street Hospital and the Middlesex Hospital. Ethical approval for the study was obtained and parents gave informed consent. Two ethnically matched healthy control populations were used for this case/control study. One population was composed of first time blood donors attending the national blood transfusion centre in London (n = 248). The second population was collected from individuals in the 16 to 30 years age group from a GP practice in a stable population of the west Midlands (n = 225).

Genotyping
DNA from 172 patients with sJIA and 473 unaffected controls was genotyped for the IL19+13735 (rs2243191) and IL20-468 (rs1400986) SNPs, and two previously characterized SNPs in IL10, IL10-592 (rs1800872) and IL10-1082 (rs1800896).

Pyrosequencing was used to genotype the polymorphisms in IL10. A fragment 50 to 200 bp flanking the SNP was PCR amplified. The anti-sense primer was biotinylated to allow the preparation of single-stranded DNA. An aliquot of 25 ng of DNA was amplified in a 25 μl PCR reaction with 0.25 μM of each primer, 0.2 mM of each of the four dNTPs, 0.5 U of Taq polymerase (Promega, Madison WI USA), 2.5 mM of MgCl₂ and 1× KCl buffer. The cycling parameters consisted of an initial denaturation at 94°C for 5 minutes and then 35 cycles of 30 s denaturation at 94°C, 30 s annealing at 67°C and 11 s extension at 72°C. A final extension step was carried out for 7 minutes at 72°C. We immobilized 10 μl of the PCR product on streptavidin sepharose beads (GE Healthcare, Uppsala, Sweden) and the pyrosequencing was performed according to the standard PSQ HS 96A system protocol (Pyrosequencing AB, Uppsala, Sweden).

Genotyping of the SNPs in the genes encoding IL19 and IL20 was carried out using Sequenom MassARRAY, (San Diego, CA, USA). Primers designed by RealSNP assay (Sequenom) amplified approximately 100 bp of sequence surrounding the target SNP. PCR was carried out using 1× HotStar Taq PCR buffer 2.5 mM MgCl₂ (Qiagen, Crawley, West Sussex, UK), 500 μM of each dNTP, 0.1 U Enzyme HotStar Taq polymerase (Qiagen), 100 nM primer, and 2.5 ng of genomic DNA in a total volume of 5 μl. PCR was followed by incubation with shrimp alkaline phosphatase to digest unincorporated dNTPs and primers. This product was used to carry out MassExtend reactions using flanking extend primers, dideoxynucleotides and Taq polymerase to extend the primer through the polymorphic
Finally, the extended product was purified of excess ions using an ion-exchange resin. Genotypes were acquired using a chip-based matrix-assisted laser desorption ionization-time-of-flight (MALDI-TOF) mass spectrometer.

**Association analysis**

Tests for Hardy-Weinberg equilibrium and for single locus association were performed using chi-squared statistics. Haploview was used to assess the level of LD between markers across this region by analysing control genotypes only [20]. We examined evidence for association of the four SNPs by single marker and haplotype analysis using Cocaphase software (UNPHASED) [21]. The p values have not been corrected for multiple testing since each SNP had a strong prior hypothesis for testing for association with systemic JIA.

**Results**

**Linkage disequilibrium analysis**

Analysis of LD across these markers confirms previous reports of an intermediate level of LD between IL10-1082 and IL10-592 within the IL10 promoter region (data not shown). No LD was observed between the IL10 markers and either IL19+13735 or IL20-468 SNPs, or between IL19+13735 and IL20-468. LD patterns using r² were similar in the cases (Figure 1).

**Association analysis**

All SNPs were in Hardy-Weinberg equilibrium in cases and controls. Significant differences in allele frequency were observed between sJIA cases and controls for IL10-1082 (p = 0.031). The association was not, however, due to the ATA haplotype, as no further genotype or haplotype effects were observed with IL10-592. Significant differences in allele frequency were also observed for the IL20 marker IL20-468 (p = 0.028; Table 1). When the two associated markers were examined as a haplotype there was an increased level of significance in association with disease (global p = 0.0006). Analysis of the haplotype frequencies revealed a decrease of the common haplotype in the cases, along with an increase in the carriage of the rare haplotype containing the low expressing 'A' allele variant of IL10-1082 and the rare 'T' allele of IL20-468 (Table 2).

There was no evidence of interaction between these SNPs. Each copy of IL10-1082A confers an increased risk of 1.3 of developing sJIA, and each copy of IL20-468T confers a risk of 1.507, with a combined risk of 2.24 across both SNPs.

The IL10-592 SNP and IL19+13735 SNPs show no significant association with sJIA.

**Table 1**

| Marker                  | Allele 1 | Allele 2 | Allele 1 | Allele 2 | Odds ratio | p value |
|-------------------------|----------|----------|----------|----------|------------|---------|
| IL10-1082G/A (allele 1 = G; allele 2 = A) | 139 (0.49) | 169 (0.55) | 425 (0.52) | 387 (0.48) | 1.335 | 0.031 |
| IL10-592C/A (allele 1 = C; allele 2 = A) | 222 (0.71) | 92 (0.29) | 647 (0.78) | 205 (0.24) | 1.308 | NS     |
| IL19+13735C/T (allele 1 = C; allele 2 = T) | 188 (0.77) | 56 (0.23) | 692 (0.78) | 194 (0.22) | 1.063 | NS     |
| IL20-468C/T (allele 1 = C; allele 2 = T) | 189 (0.79) | 51 (0.21) | 765 (0.85) | 137 (0.15) | 1.507 | 0.028 |

The numbers in the table represent the typed alleles for IL10-1082, IL10-592, IL19+13735 and IL20-468; the frequencies are in parentheses. NS, non-significant.
Discussion

A feature common to all subgroups of JIA is chronic inflammation and synovitis. Cytokines are important regulators of inflammation and many studies have shown persistent cytokine imbalance in JIA [12,22,23]. Ourselves and others have previously shown that IL6 levels in the serum and synovial fluid of sJIA patients are elevated and appear to correlate with disease activity [4,24]. Furthermore, we have replicated the case/control association study of this locus with sJIA, using the transmission disequilibrium test, confirming its role in disease susceptibility [25]. The haplotypic structure of the IL6 locus was extensively examined and we showed that a four marker haplotype has greater power in demonstrating association with sJIA susceptibility [26]. As IL10 suppresses the release of pro-inflammatory cytokines such as IL6 and TNFα, it is a normal endogenous feedback factor for the control of inflammation. Having previously identified IL10 as a marker for another severe form of JIA, extended oligoarthritis, here we aim to broaden the analysis to the IL10 gene family in sJIA using haplotype analysis.

In this study we have shown a significant increased prevalence of the IL10-1082 A allele, associated with low IL10 production, in patients with sJIA. In addition, we have also shown a separate association with another member of the IL10 gene family: IL20. The significant association of the low expressing IL10 allele with sJIA implies that the regulation of pro-inflammatory cytokine production in multiple cell types, as well as the regulation of CD4+ cells, may be suboptimal. Interaction of IL10 with other cytokines in antigen presentation and T cell polarisation pathways could determine the phenotype of the disease. For example, decreased levels of IL10 concomitant with increased IL6 would tend to favour the development of Th2 T helper cells as well as preventing the differentiation of regulatory T cells (T reg) in some instances. Our earlier study of whole blood cultures of systemic JIA has shown that there is no spontaneous production of cytokines but that there may be an inadequate IL10 response to LPS stimulation compared to that of controls [11]. IL10 is produced by some T reg cells generated in the periphery (Tr1) in humans, as well as by regulatory B cells in animal models [27]. T reg have been found to increase after autologous stem cell transplantation and disease remission in sJIA [28]. Thus, there is a suggestion from these preliminary observations that the numbers of T reg are suboptimal in sJIA, and this may also play a role in the decreased IL10 levels in these patients.

Recent evidence indicates that IL19 may also play a central role in inflammation as it up-regulates monocyte derived IL6 and TNFα in mice [29]. Like IL20, IL19 is also associated with psoriasis, another inflammatory disease [18]. Although we show no evidence for association of IL19 in this study, it cannot be eliminated as a candidate gene for sJIA. An in-depth tagging SNP approach to refute or confirm any associations in this region is currently being planned.

The increased significance of the association with the IL10-1082/IL20-468 haplotype relative to the single markers may indicate a functional role of the compound haplotype in disease susceptibility. Alternatively, it could be that neither the IL10 nor the IL20 markers are sJIA susceptibility loci, but merely in strong LD with an as yet uncharacterised functional polymorphism. There has only been limited analysis of the regulation and expression of the cluster of IL10-like genes at this locus, but this does point to a coordinated expression of these genes. Jones and Flavell [15] identified three enhancer elements in a 40 kb region between the genes encoding IL19 and IL10. Two of these enhancer elements, located 9 kb upstream and 6.45 kb downstream of the gene encoding IL10, display cell-specific function and also exhibit basic promoter activity. Hence, any polymorphism within these novel regulatory elements may alter the function or expression of any intermediate regulatory RNAs. The association we observe for the IL10-1082/IL20-468 haplotype may be attributable to any one of these regulatory regions carried on this haplotype.

Due to the low prevalence of sJIA, the number of cases used in this study is restricted. To compensate for the limited case collection, we have used a control : case ratio of 2.75 to increase the power of the study. Additional patient samples will be needed to confirm this finding in a replication study.

Conclusion

This study describes a new association between the two IL10 gene family members and children with sJIA, indicative of a central role for these cytokines in disease pathogenesis.
Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
MF conducted the genotyping using Pyrosequencing and performed the association analyses. AG helped with the genotyping. EO contributed and advised on the data analyses and helped to draft the manuscript. CS performed the Haploview analysis. JS advised on the molecular biology aspects of the project and helped to draft the manuscript. WT and LM were involved in the Sequenom genotyping. CL contributed and advised on the data analyses and helped to draft the manuscript. PW participated in the design and coordination of the study and helped to draft the manuscript.

Acknowledgements
This work was supported by the UK Arthritis Research Campaign (ARC). We acknowledge the contributors to the British Paediatric Rheumatology Study Group: Dr M Abinun, Dr M Becker, Dr A Bell, Professor A Craft, Dr E Crawley, Dr J David, Dr H Foster, Dr J Gardener-Medwin, Dr J Griffin, Dr A Hall, Dr M Hall, Dr A Herrick, Dr P Hollingworth, Dr L Holt, Dr S Jones, Dr G Pountain, Dr C Ryder, Professor T Southwood, Dr I Stewart, Dr H Venning, Dr L Wedderburn, Professor P Woo and Dr S Wyatt.

References
1. Symmons DP, Jones M, Osborne J, Sills J, Southwood TR, Woo P: Pediatric rheumatology in the United Kingdom: data from the British Paediatric Rheumatology Group National Diagnostic Register. J Rheumatol 1998, 25:1975-1980.
2. Petty RE, Southwood TR, Baum J, Bhettay E, Glass DN, Manners P, Maldonado-Cocco J, Suarez-Almazor M, Orozco-Alcala J, Prieur AM: Revision of the proposed classification criteria for juvenile idiopathic arthritis: Durban, 1997. J Rheumatol 1998, 25:1991-1994.
3. Glass DN, Giannini EH: Juvenile rheumatoid arthritis as a complex genetic trait. Arthritis Rheum 1994, 42:2261-2266.
4. Fishman D, Foulds G, Jeffery R, Mohamed-Ali V, Yudkin JS, Humphries S, Woo P: The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 1999, 102:1389-1397.
5. Dorn R, Aloufi Z, De Benedetti F, Mezza C, Zeggini E, Lunt M, Stevens A, Shelley E, Lamb R, Ollier WE, et al.: Mutation screening of the macrophage migration inhibitory factor gene: positive association of a functional polymorphism of macrophage migration inhibitor factor with juvenile idiopathic arthritis. Arthritis Rheum 2002, 46:2402-2409.
6. de Waal Malefyt R, Abrams J, Bennett B, Figdor CG, de Vries JE: Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med 1991, 174:1209-1220.
7. Noble KE, Harkness D, Yong KL: Interleukin 10 regulates cellular responses in monocyte/endothelial cell co-cultures. Br J Haematol 2000, 108:497-504.
8. Moore KW, de Waal Malefyt R, Coffman RL, O’Garra A: Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 2001, 19:883-765.
9. Turner DM, Williams DM, Sankaran D, Lazarus M, Sinnott PJ, Hutchinson IV: An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet 1997, 24:1-8.
10. Crawley E, Kay R, Stillobourne J, Patel P, Hutchinson I, Woo P: Polymorphic haplotypes of the interleukin-10 5’ flanking region determine variable interleukin-10 transcription and are associated with particular phenotypes of juvenile rheumatoid arthritis. Arthritis Rheum 1999, 42:1101-1108.
11. Muller K, Hemer EB, Stagg A, Bendtzen K, Woo P: Inflammatory cytokines and cytokine antagonists in whole blood cultures of patients with systemic juvenile chronic arthritis. Br J Rheumatol 1998, 37:562-569.
12. Crawley E, Kon S, Woo P: Hereditary predisposition to low interleukin-10 production in children with extended oligoarticular juvenile idiopathic arthritis. Rheumatology (Oxford) 2001, 40:574-578.
13. Westendorp RG, Langemans JA, Huizinga TW, Elouali AH, Verwei CL, Boommaa DI, Vandenbroucke JP: Genetic influence on cytokine production and fatal meningocephalitis disease. Lancet 1997, 349:170-173.
14. Franchimont D, Martens H, Hagelstein MT, Louis E, Dewe W, Chrousos GP, Belaiche J, Geenen V: Tumor necrosis factor alpha decreases, and interleukin-10 increases, the sensitivity of human monocytes to dexamethasone: potential regulation of the glucocorticoid receptor. J Clin Endocrinol Metab 1999, 84:2834-2839.
15. EA, Flavell RA: Distal enhancer elements transcribe intergenic RNA in the IL-10 family gene cluster. J Immunol 2005, 175:7437-7446.
16. Conti P, Kemparaj D, Frydas S, Kandere K, Boucher W, Letourneau R, Madhappan B, Sagimoto K, Christodoulou S, Theoharides TC: IL-10 null mice exhibit increased susceptibility to cyclophosphamide-induced apoptosis through TNF-alpha. J Rheumatol 2003, 30:2223-2234.
17. Oral HB, Kotonen SV, Yilmaz M, Mani O, Zumkehr J, Blaser KA, Akdis CA, Akdis M: Regulation of T cells and cytokines by the interleukin-10 (IL-10)-family cytokines IL-19, IL-20, IL-22, IL-24 and IL-26. Eur J Immunol 2006, 36:380-388.
18. Koks S, Kingo K, Vabrit K, Ratspe R, Karelson M, Silm H, Vaser E: Possible relations between the polymorphisms of the cytokines IL-19, IL-20 and IL-24 and plaque-type psoriasis. Genes Immun 2005, 6:407-415.
19. Oleksyk TK, Thio CL, Truelove AL, Goedert JJ, Donfield SM, Kirk GD, Thomas DL, O’Brien SJ, Smith MW: Single nucleotide polymorphisms and haplotypes in the IL10 region associated with HCV clearance. Genes Immun 2005, 6:347-357.
20. Barrett JC, Fry B, Maller J, Daly MJ: Haplovipe: analysis and visualization of LD and haplotype maps. Bioinformatics 2005, 21:263-265.
21. Dudbridge F: Pedigree disequilibrium tests for multilocus haplotypes. Genet Epidemiol 2003, 25:115-121.
22. De Benedetti F, Robbioni P, Massa M, Viola S, Albani S, Martini A: Serum interleukin-6 levels and joint involvement in polyarticular and pauciarticular juvenile chronic arthritis. Clin Exp Rheumatol 1992, 10:493-498.
23. de Benedetti F, Pignatti P, Massa M, Saritrapa P, Ravelli A, Martini A: Circulating levels of interleukin 1 beta and of interleukin 1 receptor antagonist in systemic juvenile chronic arthritis. Clin Exp Rheumatol 1995, 13:779-784.
24. De Benedetti F, Massa M, Robbioni P, Ravelli A, Burgio GR, Martini A: Correlation of serum interleukin-6 levels with joint involvement and thrombomodulin in systemic juvenile rheumatoid arthritis. Arthritis Rheum 1991, 34:1158-1163.
25. Ogilvie EM, Fife MS, Thompson SD, Twine N, Torsor M, Moroldo M, Fisher SA, Lewis CM, Prieur AM, Glass DN, et al.: The -174G allele of the interleukin-6 gene confers susceptibility to systemic arthritis in children: A multicenter study using simplex and multiplex juvenile idiopathic arthritis families. Arthritis Rheum 2003, 48:3202-3206.
26. Fife MS, Ogilvie EM, Kelberman D, Samuel J, Gutierrez A, Humphries SE, Woo P: Novel IL-6 haplotypes and disease association. Genes Immun 2005, 6:347-357.
27. Dieckmann D, Bruett CH, Ploettner H, Lutz MB, Schuler G: Human CD4(+)CD25(+) regulatory, contact-dependent T cells induce interleukin-10 producing, contact-independent type 1-like regulatory T cells (corrected). J Exp Med 2002, 196:247-253.
28. de Kleer I, Vastert B, Klein M, Teklenburg G, Arkesteyn G, Yung GP, Albani S, Kuis W, Wulfnaart F, Prakken B: Autologous stem cell transplantation for autoimmune induces immunologic self-tolerance by reprogramming autoreactive T cells and restoring the CD4(+)CD25(+) immune regulatory network. Blood 2006, 107:1696-1702.
29. Liao YC, Liang WG, Chen FW, Hsu HJ, Yang JJ, Chang MS: IL-19 induces production of IL-6 and TNF-alpha and results in cell apoptosis through TNF-alpha. J Immunol 2002, 169:4288-4297.